Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition
Ragnum, Harald Bull
Julin, Cathinka Halle
Frikstad, Kari-Anne Myrum
Ree, Anne Hansen
MetadataShow full item record
Background: Histone deacetylase inhibitors (HDACis) like vorinostat are promising radiosensitisers in prostate cancer, but their effect under hypoxia is not known. We investigated gene expression associated with radiosensitisation of normoxic and hypoxic prostate cancer cells by vorinostat. Methods: Cells were exposed to vorinostat under normoxia or hypoxia and subjected to gene expression profiling before irradiation and clonogenic survival analysis. Results: Pretreatment with vorinostat led to radiosensitisation of the intrinsically radioresistant DU 145 cells, but not the radiosensitive PC-3 and 22Rv1 cells, and was independent of hypoxia status. Knockdown experiments showed that the sensitisation was not caused by repression of hypoxia-inducible factor HIF1 or tumour protein TP53. Global deregulation of DNA repair and chromatin organisation genes was associated with radiosensitisation under both normoxia and hypoxia. A radiosensitisation signature with expression changes of 56 genes was generated and valid for both conditions. For eight signature genes, baseline expression also correlated with sensitisation, showing potential as pretreatment biomarker. The hypoxia independence of the signature was confirmed in a clinical data set. Conclusions: Pretreatment with HDACi may overcome radioresistance of hypoxic prostate tumours by similar mechanisms as under normoxia. We propose a gene signature to predict radiosensitising effects independent of hypoxia status.
Is part ofBritish Journal of Cancer, 2016, vol. 115, num. 8, p. 929-939
European research projects
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as cc-by-nc-sa (c) Jonsson, Marte et al., 2016
Showing items related by title, author, creator and subject.
Combination of Vorinostat and caspase-8 inhibition exhibitshigh anti-tumoral activity on endometrial cancer cells Eritja Sánchez, Núria; Bergadà Bertran, Laura; Sorolla Bardají, Anabel; Yeramian Hakim, Andree; Mirantes, Cristina; Matias-Guiu, Xavier; Dolcet Roca, Xavier (Elsevier, 2013)Histone deacetylase inhibitors such as Vorinostat display anti-neoplastic activity against avariety of solid tumors. Here, we have investigated the anti-tumoral activity of Vorinostaton endometrial cancer cells. We have ...
Expression of somatostatin receptors in human melanoma cell lines: effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation Martínez Alonso, Montserrat; Llecha Cano, Núria; Mayorga Mayorga, Maritza Elfride; Sorolla Bardají, Anabel; Dolcet Roca, Xavier; Sanmartín Novell, Verònica; Abal Diaz, Leandro; Casanova i Seuma, Josep M. (Josep Manel); Baradad Brusau, Manuel; Yeramian Hakim, Andree; Egido Garcia, Ramon Maria; Puig, Susana; Vilella, Ramón; Matias-Guiu, Xavier; Martí Laborda, Rosa Ma. (Field House Publishing, 2009)Somatostatin analogues (SAs) are potential anticancer agents. This study was designed to investigate the expression of somatostatin receptors (SSTRs) in melanoma cells and the effect of two SAs on cell proliferation and ...
Eritja Sánchez, Núria; Chen, Bo-Juen; Rodríguez Barrueco, Ruth; Santacana Espasa, Maria; Gatius Calderó, Sònia; Vidal, August; Martí, Maria Dolores; Ponce, Jordi; Bergadà Bertran, Laura; Yeramian Hakim, Andree; Encinas Martín, Mario; Ribera i Calvet, Joan; Reventós, Jaume; Boyd, Jeff; Villanueva, Alberto; Matias-Guiu, Xavier; Dolcet Roca, Xavier; Llobet Navàs, David (Taylor & Francis, 2017)Targeted therapies in endometrial cancer (EC) using kinase inhibitors rarely result in complete tumor remission and are frequently challenged by the appearance of refractory cell clones, eventually resulting in disease ...